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Phthalates, diesters of phthalic acid, are 
ubiquitous environmental chemicals. They
are components of many consumables,
including personal-care products (e.g., per-
fumes, lotions, cosmetics), paints, industrial
plastics, and certain medical devices and
pharmaceuticals [Agency for Toxic Substances
and Disease Registry (ATSDR) 1995, 1997,
2001, 2002; David et al. 2001]. Phthalates are
commonly added to these commercial prod-
ucts to hold color or fragrance, to provide a
film or gloss, to make certain plastics more
ﬂexible, or in the case of some pharmaceuti-
cals, to provide timed releases (ATSDR 1995,
1997, 2001, 2002).
The potential for nonoccupational expo-
sure to phthalates is high given their use in a
vast range of consumable products and
because they are not covalently bound to the
other chemicals in the formulations. After
exposure, phthalates are rapidly hydrolyzed to
their respective monoesters, which can be fur-
ther biotransformed to oxidative metabolites,
depending on the phthalate; all of these
metabolites can be glucuronidated and
excreted in the urine and feces (ATSDR
1995, 1997, 2001, 2002).
Phthalates are of concern in environmen-
tal public health because of their potential for
human exposure and results of animal toxicity
studies. Some phthalates and their metabolic
products act functionally as antiandrogens
during the prenatal period (Moore et al.
2001; Mylchreest et al. 1998; Parks et al.
2000) and cause reproductive and develop-
mental toxicities in animals, especially in
males. Some developmental effects include
reduction in androgen-dependent tissues
(e.g., seminal vesicles, epididymus, prostate,
and anogenital distance) (Agarwal et al.
1986; Ema and Miyawaki 2001; Foster et al.
2001; Mylchreest et al. 2000). Gestational
and lactational exposures to large doses of
dibutyl phthalate (DBP) and its metabolite
monobutyl phthalate (MBP) in rats cause
male reproductive tract malformations (Ema
and Miyawaki 2001; Mylchreest et al. 1998).
DBP reduces the production of testosterone
by the fetal testis through an antiandrogenic
mechanism (Mylchreest et al. 2002). Studies
in male rodents exposed to high doses of di-
(2-ethylhexyl) phthalate (DEHP) clearly
indicate that the testes are a primary target
tissue, resulting in decreased testicular
weights and tubular atrophy (ATSDR 2002).
The active testicular toxicant may be the
DEHP metabolite mono-2-ethylhexyl phtha-
late (MEHP) (Gray and Beamand 1984;
Gray and Gangolli 1986).
Few studies of the reproductive effects of
DEHP on females have been conducted, but
data suggest that long-term exposures of adult
female rats also appear to have deleterious
effects, including hypoestrogenic anovulatory
cycles and polycystic ovaries (Davis et al.
1994). A recent study suggests that DEHP,
through MEHP, suppresses estradiol produc-
tion in the ovary, leading to anovulation
(Lovekamp-Swan and Davis 2003). In turn,
exposure to high doses of DBP results in
spontaneous abortion of rat pups, demas-
culinization of fetal male rats, and testicular
atrophy in rats, mice, ferrets, and guinea pigs
(ATSDR 2001; Mylchreest et al. 1998).
Several phthalates also are carcinogenic in
rodents (ATSDR 2002; Huber et al. 1996;
Kluwe et al. 1982). DEHP, DBP, and their
monoester metabolites appear to have the great-
est potential toxicity. DEHP is a peroxisome-
proliferator hepatocarcinogen in rodents
(ATSDR 2002), but the relevance of carcino-
genicity by this mechanism in humans is debat-
able (Doull et al. 1999; Melnick 2001).
Despite the fact that the potential for
nonoccupational exposure to phthalates is high,
little information is known about the effects of
phthalate exposure to humans. In 2000, the
ﬁrst expert panel of the National Toxicology
Program’s Center for the Evaluation of the
Risks to Human Reproduction (CERHR)
evaluated evidence that exposure to phthalates
may result in reproductive or developmental
risks to humans. The CERHR panel con-
cluded that more data regarding human
exposure are needed for evaluating the poten-
tial health effects associated with phthalate
exposures (CERHR 2000a, 2000b, 2000c,
2000d, 2000e, 2000f, 2000g). We are collect-
ing such exposure information primarily
through our participation in the National
Health and Nutrition Examination Surveys
(NHANES), which allows us to have access
to urine and serum samples from a represen-
tative sampling of the civilian, noninstitu-
tionalized U.S. population. NHANES is an
ongoing national survey, conducted by the
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Phthalates are a group of industrial chemicals with many commercial uses, such as solvents, additives,
and plasticizers. For example, di-(2-ethylhexyl) phthalate (DEHP) is added in varying amounts to
certain plastics, such as polyvinyl chloride, to increase their ﬂexibility. In humans, phthalates are
metabolized to their respective monoesters, conjugated, and eliminated. However, despite the high
production and use of DEHP, we have recently found that the urinary levels of the DEHP metabo-
lite mono-(2-ethylhexyl) phthalate (MEHP) in 2,541 persons in the United States were lower than
we anticipated, especially when compared with urinary metabolite levels of other commonly used
phthalates. This ﬁnding raised questions about the sensitivity of this biomarker for assessing DEHP
exposure. We explored the utility of two other DEHP metabolites, mono-(2-ethyl-5-oxohexyl)
phthalate (MEOHP) and mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), as additional
DEHP biomarkers. These metabolites are formed by oxidative metabolism of MEHP. In urine
from 62 people, both the range and the mean urinary levels of MEOHP and MEHHP were on
average 4-fold higher than those of MEHP; the mean of the individual ratios of
MEHHP/MEOHP, MEHHP/MEHP, and MEOHP/MEHP were 1.4, 8.2, and 5.9, respectively.
These data suggest that MEOHP and MEHHP are more sensitive biomarkers of exposure to
DEHP than is MEHP. These findings also suggest a predominant human metabolic route for
DEHP hydrolysis to MEHP followed by oxidation of MEHP; they also imply that a similar mecha-
nism may be relevant for other high-molecular–weight phthalates, such as di-n-octyl, di-isononyl,
and di-isodecyl phthalates. Key words: DEHP, exposure, human, phthalate, urine. Environ Health
Perspect 111:1148–1151 (2003). doi:10.1289/ehp.6074 available via http://dx.doi.org/ [Online
24 February 2003]National Center for Health Statistics of the
Centers for Disease Control and Prevention
(CDC) and is designed to collect data on the
health and nutritional status of the U.S. pop-
ulation. NHANES is unique in its ability to
examine public health issues that can be
addressed through physical and laboratory
examinations of the U.S. population, such as
the assessment of exposure to environmental
chemicals (National Center for Health
Statistics 2003).
Measuring Human Exposure 
to Phthalates
Understanding human exposure to phthalates
requires information on the concentration of
these toxicants in the nonoccupationally
exposed population and on the pharmaco-
kinetics of the various phthalates. However,
because phthalates are usual laboratory conta-
minants, human studies using the parent
phthalates as biomarkers of exposure have
been primarily limited to highly exposed
populations (Ching et al. 1981; Dirven et al.
1993; Faouzi et al. 1999; Mettang et al.
1996; Pollack et al. 1985). In 2000, we
reported a novel approach, which uses phtha-
late monoester metabolites as biomarkers of
exposure to phthalates (Blount et al. 2000a).
By analyzing urine for the phthalate
monoesters, we avoided contamination from
the ubiquitous parent compounds, thus
allowing for the assessment of phthalate expo-
sure to the general population (Blount et al.
2000b; CDC 2001, 2003).
Recently, we reported the levels of seven
urinary phthalate monoester metabolites in
three subsets of NHANES participants
(Blount et al. 2000b; CDC 2001, 2003);
however, because the concentration data in
the 2001 report were included in the 2003
report, we hereafter refer only to the 2003
report. In our first study (Blount et al.
2000b), we analyzed a nonrepresentative, call-
back adult cohort of 289 urine samples, col-
lected during 1988–1994 for NHANES III.
Interestingly, we found detectable levels of
several phthalate monoesters in > 75% of the
study population. The high-molecular–weight
phthalate monoesters [e.g., MEHP, monooctyl
phthalate (MOP), monoisononyl phthalate
(MINP)] were detected less frequently and at
lower concentrations than were the low-mole-
cular–weight phthalates [e.g., monoethyl
phthalate (MEP), MBP, monobenzyl phtha-
late (MBzP)] (Blount et al. 2000b). Because
of the small sample size and nonrepresentative
nature of the NHANES III call-back subset
population, further investigation was war-
ranted to confirm our findings and to allow
more detailed analyses to describe exposure
levels in population subgroups. In January
2003, we published a detailed analysis of uri-
nary concentrations of these seven urinary
phthalate monoesters from a representative
subset of a combined group of the NHANES
1999 and 2000 samples corresponding to
2,541 persons 6 years of age and older (CDC
2003). Consistent with the findings in the
nonrepresentative NHANES III population,
we found that MEP, MBP, and MBzP were
the monoesters with the highest urinary levels
and most frequently detected in the NHANES
1999/2000 representative population (CDC
2003). However, the means and median uri-
nary concentrations of MEP, MBP, and MBzP
in the NHANES 1999/2000 population were
lower than in the NHANES III subset popula-
tion (Table 1). These ﬁndings may be related
to the small size and nonrepresentative nature
of the sampling for the earlier NHANES III
study, but it could also be due to a decrease in
exposure to diethyl phthalate (DEP), DBP,
and butylbenzyl phthalate for the population
represented by NHANES 1999/2000 data.
Nonetheless, these NHANES data conﬁrmed
that human exposure to phthalates is wide-
spread, but that there were unexplained reasons
why the concentrations of the lower-molecular–
weight phthalates tended to be greater than the
higher-molecular–weight phthalates. This
could be due to relative differences in the
amounts of the phthalates used, the degree of
human exposure, the pathways and routes of
exposure, and pharmacokinetic factors—
absorption, distribution, metabolism (biotrans-
formation), and elimination. We recognize
that any or all of these relative differences could
contribute to the large relative difference in
urinary concentrations between, for example,
MEHP and MBP. However, because our pri-
mary mission is to assess human exposure
through biomonitoring, we are particularly
interested in the fate of the chemical after it is
absorbed into the body. We therefore concen-
trated our efforts in examining differences in
distribution, metabolism, and elimination,
with particular emphasis on differences in
metabolism among the various phthalates. The
relatively polar and low-molecular–weight
phthalates (e.g., DBP) primarily metabolize
into their monoesters and are excreted (Albro
and Moore 1974; ATSDR 1995, 2001). In
contrast, the higher-molecular–weight phtha-
lates [e.g., DEHP, di-n-octyl phthalate
(DOP), di-isononyl phthalate (DINP)] are
hydrolyzed to their respective monoesters,
which, in a multistep oxidative pathway (i.e.,
[ω-1]- and ω-oxidation of the aliphatic side
chain), are metabolized to more hydrophilic,
oxidative metabolites (Albro et al. 1973;
Albro and Lavenhar 1989; Albro and Thomas
1973; ATSDR 1997, 2002; McKee et al.
2002).
Sensitive Biomarkers of
Exposure to DEHP
Human exposure to DEHP should be rela-
tively high because this compound is com-
monly used as a plasticizer to improve the
ﬂexibility of polyvinyl chloride (PVC). DEHP
is found in such PVC materials as wall cover-
ings, ﬂoor tiles, furniture upholstery, packaging
ﬁlm and sheets, blood storage bags, and med-
ical tubing, including that used for administer-
ing parenteral solutions and in hemodialysis
treatments (ATSDR 2002). The relatively low
levels of MEHP in urine raised the question of
whether MEHP is the most sensitive bio-
marker for assessing DEHP exposure and
prompted us to assess the utility of other
DEHP metabolites as alternative DEHP bio-
markers. Mono-(2-ethyl-5-oxohexyl)phthalate
(MEOHP) and mono (2-ethyl-5-hydroxy-
hexyl)phthalate (MEHHP) are known DEHP
metabolites in mammals (Albro et al. 1973;
Albro and Lavenhar 1989; ATSDR 2002;
Egestad et al. 1996). Four major DEHP
metabolites—MEHP, MEOHP, MEHHP,
and mono-(5-carboxy-2-ethylpentyl)phthalate
(MCEPP)—were found in the urine of persons
exposed to DEHP (Albro et al. 1982; Dirven
et al. 1993; Schmid and Schlatter 1985); the
half-life of DEHP was estimated to be about
12 hr (Schmid and Schlatter 1985). In all of
these studies, conducted on a limited number
of persons, MEHHP and MEOHP concentra-
tions in urine were higher than MEHP con-
centrations after oral (Schmid and Schlatter
1985), intravenous (Albro et al. 1982), and
occupational (Dirven et al. 1993) exposure to
DEHP. MCEPP concentrations were higher
than those of MEHP in urine only after oral
administration of DEHP (Dirven et al. 1993).
These results suggested that MEHHP and
MEOHP might be useful biomarkers of expo-
sure to DEHP. To test this hypothesis, we
evaluated exposure to DEHP in 62 persons,
children and adults, by measuring MEHP,
MEOHP, and MEHHP in urine using an
adaptation (Silva et al. 2003) of our isotope-
dilution HPLC–tandem mass spectrometry
method (Blount et al. 2000a). The limits of
detection in urine were 1.2 ng/mL MEOHP,
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Table 1. Median urinary levels of monoester phthalate metabolites in the U.S. population (µg/L).
Analyte NHANES IIIa NHANES 1999–2000b NHANES 1999–2000c
MEP 305.0 164.0 180.0
MBP 41.0 26.0 23.0
MBzP 21.2 17.0 13.8
MEHP 2.7 3.2 3.0
aNonrepresentative call-back cohort of 289 adults. bRepresentative sample of the U.S. population (2,541 persons 6 years
of age and older). cRepresentative sample of the adult U.S. population (1,461 persons 20 years of age and older).1.6 ng/mL MEHHP, and 0.9 ng/mL MEHP
(Silva et al. 2003).
The assessment of exposure to a given
chemical using urinary concentrations of its
metabolites is a somewhat tenuous process. For
example, data suggest that phthalates are rapidly
metabolized to their respective monoesters.
The metabolism of lower-molecular–weight
phthalates ends with the monoester (Albro
and Moore 1974; ATSDR 1995, 2001), but
the metabolism of the higher-molecular–
weight phthalates continues with transforma-
tion of the monoester to oxidative products
(Albro et al. 1973; Albro and Lavenhar 1989;
Albro and Thomas 1973; ATSDR 1997,
2002; McKee et al. 2002). In this study of 62
urine samples, we found that all three DEHP
metabolites were frequently detected (MEHP
in 50; MEHHP in 59; MEOHP in 60).
Because only 50 of the samples had
detectable levels for all three metabolites, sta-
tistical analyses were limited to those 50. We
ﬁrst analyzed the data on a population basis.
The concentration values were not normally
distributed. The medians (and ranges) of
concentrations were 4.5 ng/mL (1.4–537
ng/mL) for MEHP, 28.3 ng/mL (4.2–1,860
ng/mL) for MEOHP, and 35.9 ng/mL
(2.7–2,417 ng/mL) for MEHHP. The uri-
nary mean concentrations of MEHHP and
MEOHP were 4.3-fold (p < 0.02) and 3.3-
fold (p < 0.03) higher, respectively, than the
mean concentration of MEHP. Furthermore,
the concentrations of MEOHP and MEHHP
were highly correlated [correlation coefﬁcient
of the linear regression (r2) = 0.984; Figure 1]
and correlated to those of MEHP (r2 ~ 0.9;
Figure 1). We also analyzed the data by com-
paring the ratios of the concentrations of the
metabolites within each of the 50 individuals.
The respective mean ratios [and relative stan-
dard deviations (RSDs)] of metabolites con-
centrations were MEHHP/MEOHP = 1.4
(22%), MEHHP/MEHP = 8.2 (80%), and
MEOHP/MEHP = 5.9 (74%). These data
indicate that when MEHP is further metabo-
lized, the two oxidative metabolites are
formed very consistently among individuals,
as evidenced by the relative low RSD for the
MEHHP/MEOHP ratio. The much higher
RSDs for the MEHHP/MEHP and
MEOHP/MEHP ratios suggest that the
degree of oxidative metabolism varies consid-
erably among people (assuming all values
reﬂect steady state).
Future Research Priorities 
on Phthalates
The use of MEHP as a biomarker for assessing
exposure to DEHP is valid, and MEHP cer-
tainly can be used for comparing exposure to
DEHP among studies, assuming that it is pre-
sent in detectable concentrations. However,
the use of MEHP as the sole biomarker for
comparing relative exposures of DEHP to vari-
ous phthalates in a given study can be mislead-
ing. This is especially true when comparing
monoester results of the higher-molecular–
weight phthalate monoesters, such as MEHP,
with the lower-molecular–weight monoesters,
such as MEP, because the metabolism of the
higher-molecular–weight phthalates is more
complex and results in more metabolites, thus
decreasing the relative amounts of their
monoester metabolites. To properly interpret
and model the data (David 2000; Kohn et al.
2000; Koo et al. 2002), one must have knowl-
edge of the pharmacokinetics of each of the
phthalates. For example, the higher urinary
concentrations and frequency of detection of
the oxidative DEHP metabolites MEOHP and
MEHHP relative to that of MEHP suggest
that the two oxidative metabolites are more
sensitive indicators of DEHP exposure than is
MEHP alone and that exposure to DEHP may
be higher than previously thought based on the
NHANES data, which measured MEHP only.
Another way to better assess the dose, espe-
cially the relative dose, of DEHP is to measure
the concentrations of MEHP, MEOHP, and
MEHHP. We are currently doing this.
Likewise, we speculate that the lower uri-
nary levels of MOP and MINP found in the
NHANES studies may not necessarily reﬂect
lower exposure to DOP and DINP, respec-
tively, although the former may not be highly
used. As with DEHP, these phthalates initially
metabolize into their monoesters, which then
form oxidative phthalate monoesters; these are
the major metabolites detected in the urine
(Albro and Moore 1974; McKee et al. 2002).
Additional research needs to focus on the
oxidative metabolites of DOP, DINP, and the
other high-molecular–weight phthalates.
It is important to note that MEHP pos-
sesses biologically relevant activity. Therefore,
MEHP is a valid DEHP biomarker when
looking at health end points. To date, no infor-
mation on the biological activity of the oxida-
tive metabolites is available. It is conceivable
that oxidative metabolism reduces the toxicity
of the higher-molecular–weight phthalates.
Further research to establish the bioactivity of
MEHHP and MEOHP is warranted.
Our data support the widespread nature
of human exposure to phthalates. However,
the measurement of phthalate metabolites in
people does not by itself mean that phthalates
cause disease. Additional research is required
to determine whether exposure to phthalates
at the levels found in the general population
is a cause for health concern.
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Figure 1. Relationship between the urinary concen-
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